Skip to main content

Dermatologic & Topical Urethral Pharmacotherapy

Topical and intralesional therapies for genital dermatoses (lichen sclerosus, lichen planus, plasma-cell balanitis), urethral-stricture prevention and adjunctive therapy, and regenerative urologic applications. The category includes high-potency topical corticosteroids (the LS workhorse), topical calcineurin inhibitors (steroid-sparing), selected intralesional treatments and investigational stricture adjuncts, the Optilume drug-coated balloon (paclitaxel) as a stricture-recurrence-prevention platform, and platelet-rich plasma as an investigational biologic.

For oral systemic Peyronie's pharmacotherapy see Sexual Medicine & Andrology — Peyronie's Disease Agents. For lichen sclerosus clinical management see the linked condition page.

  • High-Potency Topical CorticosteroidsClobetasol propionate 0.05% as the LS workhorse — induction, maintenance, and site-specific steroid safety and label boundaries. Comparative potency table (clobetasol, halobetasol, betamethasone dipropionate, fluocinonide, mometasone). Pediatric dosing; balanitis-xerotica-obliterans (BXO) protocols.
  • Topical Calcineurin InhibitorsTacrolimus (Protopic) 0.1%/0.03% and pimecrolimus (Elidel) 1% as steroid-sparing options for genital dermatoses. Off-label in LS and lichen planus; FDA boxed warning on theoretical lymphoma risk and the contemporary safety re-evaluation; intermittent maintenance regimens.
  • Intralesional CorticosteroidsTriamcinolone for Hunner lesions and selected specialist applications. Off-label formulation limits; uncertain stricture/BNC benefit; systemic absorption and pediatric safety.
  • Antimitotics & AntifibroticsMitomycin C, paclitaxel and experimental antifibrotic approaches. Clinical-trial boundaries for stricture injections, necrosis/fistula cautions and the DCB evidence comparison.
  • Drug-Coated Balloon Therapy (Optilume)Optilume (paclitaxel): US anterior-stricture label versus recurrent bulbar guideline selection, ROBUST trials, device instructions and required contraception counseling.
  • Platelet-Rich Plasma (PRP)Investigational PRP in bladder pain, ED, stricture, incontinence and genital disease. Conflicting controlled trials, uncontrolled-study limitations and preparation safety.
  • HPV / Condyloma Topical AgentsImiquimod (TLR7 agonist), sinecatechins (green-tea EGCG), podophyllotoxin / podophyllin, trichloroacetic acid, topical 5-FU for anogenital warts and HPV-driven lesions. Patient- vs clinician-applied, pregnancy precautions, immunosuppressed-patient regimens, intraurethral and meatal lesion considerations, HPV-vaccine prevention.